CurisCRIS
About: Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Employees: 49
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
3.66% more ownership
Funds ownership: 35.47% [Q1] → 39.13% (+3.66%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
6% less funds holding
Funds holding: 36 [Q1] → 34 (-2) [Q2]
30% less capital invested
Capital invested by funds: $22.7M [Q1] → $15.9M (-$6.81M) [Q2]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Edward White 23% 1-year accuracy 28 / 124 met price target | 387%upside $26 | Buy Reiterated | 27 Sept 2024 |
HC Wainwright & Co. Edward White 23% 1-year accuracy 28 / 124 met price target | 387%upside $26 | Buy Reiterated | 1 Aug 2024 |